Continuing activities
Cerep has extended for the year 2009 its major service agreements as well as its strategic collaborations signed in 2002 and 2003 with Pfizer and Eli Lilly & Company respectively.
The supply and co-marketing agreement signed with PerkinElmer, Inc. in April 2008 has been extended to kinases. One of the first successes of this extension is the signature with Eli Lilly & Company of a major kinase profiling agreement in June 2009.
-During the second quarter 2009, Cerep announced the signature of a 3-year collaboration agreement with Servier for the discovery and optimization of new drugs.
In October 2009, Cerep announced the signature of a BioPrint® evaluation licence with Roche. Under the terms of the agreement Roche will be granted access to the BioPrint® database and related pharmaco-informatics tools. At the end of the evaluation period, Roche will have the option to subscribe a perpetual licence at a predetermined price.

Discontinued activities
At the end of 2006, Cerep decided to refocus all efforts on the development of profitable activities only; the Company had also announced, in early 2009, its decision to stop all expenses associated to its oncology program. Financial impacts of these decisions are totally reflected in the Group results.
As part of its annual portfolio review and arbitration, sanofi-aventis decided during the first half of the year, to discontinue the program on the NPY1 antagonist co-discovered by Cerep and sanofi-aventis.
In January 2009, Cerep announced the signature of a license agreement with Thea for the development of an LFA-1 antagonist. Several months of assays and research led Thea to the conclusion that the licensed product was not appropriate for the development in ophthalmology and thus decided to discontinue this program. The termination of the license agreement triggered the payment to Cerep of a termination fee paid in January 2010.

Continuing activities
After the end of the year, the Company shares have been subject to a change of market place. As of March 19, 2010 Cerep shares have been transferred from NYSE Euronext Paris to NYSE Alternext.

Discontinued activities
In 2006, two former employees of Anceris initiated an action in a civil court, claiming damages of EUR 9 million. The Court (Paris Tribunal de Grande Instance) rendered its judgment on March 2010 and dismissed Anceris employees’claim which was judged unfounded.